1. HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance
   Yaming Du et al, 2016, Tumor Biology CrossRef
2. Narciclasine inhibits angiogenic processes by activation of Rho kinase and by downregulation of the VEGF receptor 2
   Jacqueline Bräutigam et al, 2019, Journal of Molecular and Cellular Cardiology CrossRef
3. Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications
   Elena Boggio et al, 2023, Pharmaceutics CrossRef
4. A murine–human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro
   Guipeng Ding et al, 2014, Cytotechnology CrossRef
5. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer
   Zhili Wen et al, 2021, Aging CrossRef
6. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
   Wei Huang et al, 2017, Advanced Drug Delivery Reviews CrossRef
7. Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth
   Brian Stagg et al, 2014, Cancers CrossRef
8. Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression
   Z-H Liu et al, 2015, Cell Death & Disease CrossRef
9. Recent Advances in RNA‐Targeted Cancer Therapy
   Miao Li et al, 2024, ChemBioChem CrossRef
10. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA
    Victoria Capel et al, 2018, Drug Delivery CrossRef
11. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA
    Xiaoxia Liu et al, 2014, Nucleic Acids Research CrossRef
12. EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models
    Lilian Saryeddine et al, 2016, PLOS ONE CrossRef
13. Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
    Hannah J. Vaughan et al, 2020, Advanced Materials CrossRef
14. A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts
    Lumin Liao et al, 2021, Drug Delivery CrossRef
15. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy
    Sepideh Mirzaei et al, 2021, Life Sciences CrossRef
16. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances
    Nishant S. Gandhi et al, 2014, Journal of Controlled Release CrossRef
17. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases
    Valerie Kedinger et al, 2013, BMC Cancer CrossRef